Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Operating Income (2016 - 2025)

Assembly Biosciences has reported Operating Income over the past 11 years, most recently at $19.8 million for Q4 2025.

  • Quarterly results put Operating Income at $19.8 million for Q4 2025, up 271.69% from a year ago — trailing twelve months through Dec 2025 was -$12.1 million (up 73.32% YoY), and the annual figure for FY2025 was -$12.1 million, up 73.32%.
  • Operating Income for Q4 2025 was $19.8 million at Assembly Biosciences, up from -$10.9 million in the prior quarter.
  • Over the last five years, Operating Income for ASMB hit a ceiling of $19.8 million in Q4 2025 and a floor of -$62.9 million in Q4 2021.
  • Median Operating Income over the past 5 years was -$16.3 million (2023), compared with a mean of -$17.4 million.
  • Biggest five-year swings in Operating Income: tumbled 459.72% in 2021 and later surged 271.69% in 2025.
  • Assembly Biosciences' Operating Income stood at -$62.9 million in 2021, then surged by 63.46% to -$23.0 million in 2022, then surged by 45.38% to -$12.6 million in 2023, then rose by 8.12% to -$11.5 million in 2024, then surged by 271.69% to $19.8 million in 2025.
  • The last three reported values for Operating Income were $19.8 million (Q4 2025), -$10.9 million (Q3 2025), and -$11.1 million (Q2 2025) per Business Quant data.